Zuojin Wan
Phase 1Small molecule
Zuojin Wan is one of 49 small molecule programs targeting Depression. It is currently in Phase 1.
2
Indications
2
Total Trials
2
Active Trials
48
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
42 competitors in Depression
#DrugCompanyPhaseTrials
1Cymbalta
Jazz PharmaceuticalsApproved
Brintellix
TakedaApproved
Ketalar
AAultman Health Foundation
Approved
Zoloft
VViatris Specialty LLC
Approved
Vraylar
AbbVieApproved
Prozac
VVitae Pharmaceuticals Inc., an Allergan affiliate
Approved
Wellbutrin
GGlaxo Dba Glaxosmithkline
Approved
Estrace
Novo NordiskApproved
Trexall
Jazz PharmaceuticalsApproved
Spravato
WWim Janssens
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Depression1 trial
Unspecified1 trial
Zuojin Wan Combined with Vonoprazan-Amoxicillin Dual Therapy in H.Pylori Eradication
Not yet recruiting·NNanjing First Hospital, Nanjing Medical University·Phase 1·NCT06901375·136 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Zuojin Wan. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details